In a previous report, “physical problems” were cited as a cause of loss to follow-up in patients on anti-VEGF therapy for RVO-ME, and when AMD and DME were also included, “high cost of the drug” and “no improvement in vision after treatment” were cited [8]. Here, VEGFA is linked to age-related macular degeneration.